menu
    • menu
    [{"orgOrder":0,"company":"University Hospital, Bordeaux","sponsor":"Fondation Plan Alzheimer | GE Healthcare | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Amyloid-beta plaques","graph1":"Neurology","graph2":"Phase III","graph3":"University Hospital, Bordeaux","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Bordeaux \/ Fondation Plan Alzheimer | GE Healthcare | Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"University Hospital, Bordeaux \/ Fondation Plan Alzheimer | GE Healthcare | Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Amyloid-beta plaques","graph1":"Neurology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Amyloid-beta plaques","graph1":"Neurology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Amyloid-beta plaques","graph1":"Neurology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Amyloid-beta plaques","graph1":"Neurology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Amyloid-beta plaques","graph1":"Neurology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Amyloid-beta plaques","graph1":"Neurology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Amyloid-beta plaques","graph1":"Neurology","graph2":"Phase IV","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Alzheimer's Drug Discovery Foundation | Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase IV","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of California, San Francisco \/ Alzheimer's Drug Discovery Foundation | Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Francisco \/ Alzheimer's Drug Discovery Foundation | Eli Lilly"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Florbetapir F 18","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Florbetapir F 18

    Menu

    Florbetapir F 18

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            University Hospital, Bordeaux

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University Hospital, Bordeaux

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Fondation Plan Alzheimer | GE Healthcare | Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Longitudinal Study of Brain Amyloid imaGing in MEMENTO

                            Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 16, 2014

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Fondation Plan Alzheimer | GE Healthcare | Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Florbetapir Calibration to the Centiloid Scale

                            Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 23, 2014

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Feasibility of Florbetapir Quantitation in Europe

                            Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 08, 2014

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

                            Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 08, 2014

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and N...

                            Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 01, 2013

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Sca...

                            Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 10, 2012

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteer...

                            Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 13, 2012

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Florbetapir (18F) in Japanese Healthy Volunteers

                            Details : Florbetapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 09, 2012

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of California, San Francisco

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            University of California, San Francisco

                            Country arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Alzheimer's Drug Discovery Foundation | Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Brain Beta-Amyloid on Postoperative Cognition

                            Details : Florbetapir F 18 is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Postoperative Cognitive Complications.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 25, 2012

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Alzheimer's Drug Discovery Foundation | Eli Lilly

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Eli Lilly

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of PET Scan Timing Relative to AV-45 Injection Time

                            Details : Florbetapir F 18 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 28, 2012

                            Lead Product(s) : Florbetapir F 18

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth